Valneva SE ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $966.68 million
- Book Value:
- Revenue TTM:
- $372.96 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Valneva SE ADR had its IPO on 2021-05-05 under the ticker symbol VALN.
The company operates in the Healthcare sector and Biotechnology industry. Valneva SE ADR has a staff strength of 719 employees.
Shares of Valneva SE ADR opened at $13.39 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.39 - $13.78, and closed at $13.56.
This is a -2.23% slip from the previous day's closing price.
A total volume of 3,491 shares were traded at the close of the day’s session.
In the last one week, shares of Valneva SE ADR have slipped by -2.72%.
Valneva SE ADR's Key Ratios
Valneva SE ADR has a market cap of $966.68 million, indicating a price to book ratio of 5.7635 and a price to sales ratio of 2.0179.
In the last 12-months Valneva SE ADR’s revenue was $372.96 million with a gross profit of $-68060000 and an EBITDA of $-98744000. The EBITDA ratio measures Valneva SE ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Valneva SE ADR’s operating margin was -29.96% while its return on assets stood at -10.21% with a return of equity of -76.65%.
In Q1, Valneva SE ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 53.4%.
Valneva SE ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Valneva SE ADR’s profitability.
Valneva SE ADR stock is trading at a EV to sales ratio of 1.6667 and a EV to EBITDA ratio of 9.2062. Its price to sales ratio in the trailing 12-months stood at 2.0179.
Valneva SE ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $590.00 million
- Total Liabilities
- $263.26 million
- Operating Cash Flow
- Capital Expenditure
- $3.81 million
- Dividend Payout Ratio
Valneva SE ADR ended 2023 with $590.00 million in total assets and $0 in total liabilities. Its intangible assets were valued at $590.00 million while shareholder equity stood at $204.78 million.
Valneva SE ADR ended 2023 with $0 in deferred long-term liabilities, $263.26 million in other current liabilities, in common stock, $-468380000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $254.49 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $83.23 million.
Valneva SE ADR’s total current assets stands at $389.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.02 million compared to accounts payable of $33.52 million and inventory worth $39.00 million.
In 2023, Valneva SE ADR's operating cash flow was $0 while its capital expenditure stood at $3.81 million.
Comparatively, Valneva SE ADR paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Valneva SE ADR stock is currently trading at $13.56 per share. It touched a 52-week high of $17.1 and a 52-week low of $17.1. Analysts tracking the stock have a 12-month average target price of $18.66.
Its 50-day moving average was $14.37 and 200-day moving average was $13.12 The short ratio stood at 1.21 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 58.4% are held by institutions.
Frequently Asked Questions About Valneva SE ADR
Similar Industry Stocks (Biotechnology)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.